hotspot -WSS

hotspot

author：explore 2025-09-04 04:26:06 - browse：71

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke Thursday at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

As Cytokinetics faces pressure to sell itself to a large pharma company following positive late-stage results of its heart drug, CEO Robert Blum maintains that the biotech can launch the treatment — what would be its first approved medication — on its own.

Cytokinetics reported top-line results of its drug, aficamten, in obstructive hypertrophic cardiomyopathy, or oHCM, last December, sending its shares up on speculation the company would get acquired. Full Phase 3 results released this week further suggest the drug could be used more flexibly than a similar treatment sold by Bristol Myers Squibb, but investors have questioned whether the biotech has the resources and salesforce to compete with a large pharma company.

Blum, speaking Thursday at a talk during STAT’s Breakthrough Summit West, said that if prospective buyers approach the company, he will talk to them, but “at the same time, we’re pushing forward, as we always have, with the original intention to build a commercial business. And that’s not something new. That’s not something that’s a result of a failed M&A dialogue.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Patients' immediate access to test results puts radiologists in a bind

WSS

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

How to increase colonoscopy rates? Looks like an AI can help

CMS should re

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Cord blood banking comes at a high cost to babies

Congenital heart disease patients face new threat of heart failure

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Virginia high school admissions case could be legal follow

Cord blood banking comes at a high cost to babies

ChatGPT in medicine: STAT answers readers' burning questions

Letters to First Opinion on caregivers, digital health, and more

Hollywood unions extend contract negotiations for actors

Patients' immediate access to test results puts radiologists in a bind

Heart attack and stroke risk calculators need revising

Patients' immediate access to test results puts radiologists in a bind

Tori Bowie and the unacceptable rates of Black maternal death

AI models in health care face new federal disclosure requirements

entertainment

Radiology is caught between AI's potential and concern for patients

See how much Covid

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

CMS should re

The Pandemic Treaty must support building strong health systems

HIV drugs protect against transmission, even in unprotected sex

focus

hotspot

focus

leisure time